#USA #New York #Securities Fraud #Pomerantz Law Firm #Acadia Pharmaceuticals

Investigation of Acadia Pharmaceuticals by Pomerantz Law Firm

Pomerantz LLP, a leading law firm renowned for its expertise in securities class action litigation, has launched an investigation concerning potential securities fraud claims on behalf of investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). This inquiry arises following troubling revelations involving the company’s recent clinical trials related to Alzheimer's disease.

Background on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, a biopharmaceutical company, focuses on developing innovative medicines to treat neurological and psychiatric diseases. One of its key products under examination, remlifanserin, is currently being evaluated for its effectiveness in managing hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). In its latest announcement on September 24, 2026, Acadia disclosed Phase 3 enabling topline results from the Phase 2 segment of its ongoing RADIANT clinical trial.

Details of the Investigation

The investigation by Pomerantz LLP aims to determine whether the company's officials engaged in unlawfully misleading business practices or securities fraud that could affect investors. Specifically, the focus is on the disclosures related to remlifanserin. During the trial, it was reported that the drug “narrowly missed” achieving its primary endpoint in a clinical assessment designed to gauge the severity of the disease. This announcement led to a notable decline in ACAD's stock price, which dropped $3.25 (12.78%) to $22.18 per share immediately following the update.

Following the disappointing results of the clinical trial, on September 25, 2026, multiple financial analysts downgraded ACAD, citing serious concerns based on the trial findings. This prompted a further plunge in the share price, which fell another $1.50 (6.76%) to end at $20.68 per share at the market close of the same day.

These events have raised questions among investors about the transparency of Acadia's communications and whether they adequately informed stakeholders of the risks associated with their clinical trials and product viability.

Implications for Investors

Investors who may have experienced losses due to these incidents are encouraged to reach out to Danielle Peyton at Pomerantz LLP to discuss their potential options for joining the class action. The firm’s longstanding reputation in handling securities fraud claims provides a strong basis for affected investors to seek justice and possibly recover their losses.

Pomerantz is one of the most respected firms in the domain of securities class action law, with a history of successfully recovering millions for its clients due to corporate misconduct. As noted, the firm emphasizes its commitment to fighting for the rights of victims affected by securities fraud and breaches of fiduciary duty. Their investigation may result in further legal action against ACADIA and its executives if the allegations are substantiated.

Conclusion

The investigation by Pomerantz LLP into ACADIA Pharmaceuticals highlights the complexities and risks associated with investing in biotech firms, particularly those with high-stakes clinical trials. As developments unfold, affected investors must stay informed of their potential paths for recourse and remain vigilant regarding their investment strategies in the field of pharmaceuticals.

For more detailed information regarding this investigation or to discuss your situation, please contact Pomerantz LLP directly. This could be an important step in recouping any financial damage incurred as a result of the recent events surrounding ACADIA Pharmaceuticals.